Diabetes

March 01, 2022

An expert in endocrinology reviews updates from the AMCP Nexus 2021 conference on treatment persistence and adherence with iGlarLixi versus free-dose combinations of basal insulin and GLP-1 receptor agonists, and shares insight on future directions for disease management.

March 01, 2022

Rodolfo J. Galindo, MD, comments on the benefits of fixed-ratio combination therapies for the management of type 2 diabetes compared with premixed insulin.

February 22, 2022

A key opinion leader reviews clinical data for newly approved injectable medications, iGlarLixi and iDegLira, for the management of type 2 diabetes as seen in the LixiLan-O and DUAL studies.

February 22, 2022

Rodolfo J. Galindo, MD, provides insight on the benefit of fixed-ratio combinations of basal insulin and GLP1 agonists for the optimal management of type 2 diabetes.

January 27, 2022

Dr Jennifer Brigitte Green considers the patient selection for fixed-ratio combinations of basal insulin and GLP-1 receptor agonists among patients with type 2 diabetes and provides insight around Medicare patient access to insulin and injectable medications.

January 27, 2022

Jennifer Brigitte Green, MD, discusses the reasoning behind clinical inertia in treating patients with type 2 diabetes and comments on achieving and maintaining glycemic control over an extended period.

January 20, 2022

Dr Jennifer Brigitte Green addresses clinical considerations for patients with type 2 diabetes who are not responding to their oral antidiabetic agents and discusses her strategy for insufficient target glycemic control with insulin regimens.

January 06, 2022

The cost-effectiveness group say Lilly’s diabetes treatment should have an annual price of between $5,500 and $5,700. The FDA is expected to make a decision on whether to approve tirzepatide this year.

December 22, 2021

Jennifer Brigitte Green, MD, reviews her treatment approach for managing patients with type 2 diabetes and shares insight on how to identify patients that are uncontrolled with oral antidiabetic agents.

November 09, 2021

At a placeholder cost equal to Ozempic, tirzepatide scored lower in a measure of cost-effectiveness compared with Ozempic but higher than Jardiance.